GSK (LSE:GSK) is in the midst of proving that its research engine can drive the next leg of growth. Second-quarter results in July 2026 combined solid core Earnings and a sharply expanded late-stage pipeline with a costly trial failure, capturing the twin forces at play: a specialty-medicines Business gaining momentum against the challenge of normalising Vaccine demand. The debate is over what drives the shares next.

Latest developments

On 28 July 2026 GSK (LSE:GSK) reported second-quarter total sales of £8.4bn, up 5%, and core operating profit of around £2.8bn. The company raised its research ambition, now planning more than 20 Phase III trial starts in 2026 across seven Assets and 18 indications in oncology, respiratory, hepatology and vaccines, up from 10 previously.

The quarter also brought a setback, with the discontinuation of the chronic-cough treatment camlipixant after a Phase III failure triggering a roughly £1.3bn non-cash impairment, which cut reported earnings even as core metrics held firm. GSK also confirmed completion of a £2bn buyback, signalling its intent to return Capital even as it steps up research spending — a balance the market will watch closely.

Financial and operational picture

Core Earnings Per Share rose 9% to 50.5p in the quarter, though total earnings per share fell to 10.8p because of the Impairment and other charges. Specialty Medicines grew to £3.8bn, up 14%, with strong contributions from respiratory, immunology and oncology, while Vaccines rose 8% to £2.3bn. First-half turnover was £16.0bn.

GSK guides to full-year turnover growth of 3–5% and core operating profit and core EPS growth of 7–9%, with a full-year Dividend expected at 70p.

What could drive the shares next?

The accelerated late-stage pipeline, with more than 20 Phase III starts and key readouts across oncology, respiratory and hepatology, is the main catalyst. Continued Specialty Medicines momentum offsetting declines in older products, delivery of full-year guidance and ongoing capital returns all feed the story.

The scale of the pipeline expansion signals GSK's determination to rebuild investor confidence in its research capabilities after years in which the market questioned whether it could generate enough new blockbusters. Beyond individual trial readouts, the group's ability to convert its HIV, respiratory and oncology franchises into sustained growth as older products face competition will be pivotal. The divergence between core and total earnings is instructive: core measures strip out items such as the camlipixant impairment, but the reported figures are a reminder that pipeline setbacks carry real financial consequences.

Risks to watch

Pipeline attrition is a live risk, as the camlipixant failure demonstrates, and late-stage misses can move the shares. US drug-pricing and Tariff policy remains an overhang, vaccine Demand is normalising after pandemic-era highs amid competition, and residual litigation and contingent liabilities continue to weigh on reported earnings. The company must also manage Patent expiries and the normalisation of vaccine demand at the same time, a combination that leaves little Margin for pipeline disappointment; any regulatory or safety setback for a key growth product would be felt keenly given how much of the story now rests on newer medicines.

Investor takeaway

GSK's second quarter underlined both the promise and the risk in its strategy: a fast-growing specialty business and a broadening pipeline set against binary trial outcomes and softer vaccines. The next big move will likely hinge on late-stage data, the durability of specialty growth and management's ability to deliver guidance. Investors will focus on Phase III readouts, vaccine trends and any shifts in US pricing policy as the clearest signals of direction into 2027.